| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9611267 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jan, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(9 years from now) | |
| US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(15 years from now) | |
| US11628162 | INCYTE CORP | Methods of treating cancer with an FGFR inhibitor |
Aug, 2040
(16 years from now) | |
Pemazyre is owned by Incyte Corp.
Pemazyre contains Pemigatinib.
Pemazyre has a total of 4 drug patents out of which 0 drug patents have expired.
Pemazyre was authorised for market use on 17 April, 2020.
Pemazyre is available in tablet;oral dosage forms.
Pemazyre can be used as for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement, treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg, treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib while avoiding the concomitant use of strong and moderate cyp3a inhibitors; treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib while avoiding the concomitant use of strong and moderate cyp3a inducers; treatment of relapsed or refractory myeloid/lymphoid neoplasms with fgfr1 rearrangement by administering pemigatinib while avoiding the concomitant use of strong and moderate cyp3a inducers; treatment of relapsed or refractory myeloid/lymphoid neoplasms with fgfr1 rearrangement by administering pemigatinib while avoiding the concomitant use of strong and moderate cyp3a inhibitors.
Drug patent challenges can be filed against Pemazyre from 2024-04-17.
The generics of Pemazyre are possible to be released after 30 August, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity (ODE) | Aug 26, 2029 |
| New Indication (I) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 2024-04-17
Market Authorisation Date: 17 April, 2020
Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...
Dosage: TABLET;ORAL
PEMAZYRE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic